The veterinary metabolic disease treatment market is projected to grow from USD 3.9 billion in 2026 to USD 7.5 billion by 2036, at a CAGR of 6.8%. Hormonal therapies will dominate with a 34.0% market share, while ketosis will lead the applications segment with a 38.0% share.